Clinical trial · Observational
Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
Renal Cell Cancer Registry in Latin American Clinical-phatological Characterization and Outcomes of Renal Cell Carcinoma in Latin America
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Observational study, retrospective and prospective, of an analytical nature. Data will be collected from medical records and/or through contact with physicians and institutions (secondary data collection). Patients included retrospectively or prospectively will be followed during the data collection period for the evaluation of treatments and survival. No intervention is planned in this protocol.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Neoplasms | Kidney Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observational study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with pathological diagnosis of renal cell carcinoma
- description
- Patients aged 18 years or older, who have been diagnosed with renal cell carcinoma (new case or recurrence) since January 2015 and during the study recruitment period.
- interventionNames
- Other: Observational study
Primary outcomes (1)
- measure
- Build a real-life renal cell cancer database in Brazil and Latin America
- timeFrame
- 2022
Secondary outcomes (7)
- measure
- Sociodemographic characteristics checklist
- timeFrame
- 2022
- description
- Describe sociodemographic characteristics: age at diagnosis, race, education, family income, occupation, personal habits, family history, comorbidities, treatment funding (public or private), treatment institution (public, private or philanthropic).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients ≥ 18 years of age; * Proven histology of renal cell carcinoma (any subtype); * Pathological diagnosis of renal cell carcinoma in January 2015 or later and new cases diagnosed during the period of recruitment of each center; * Have the medical record available and suitable for collecting data on patient characteristics, treatment and outcome. Exclusion Criteria: * Synchronous or other primary tumor within the last 3 years (except thyroid cancer or non melanoma skin).
References
Publications (0)
Data not yet available